Skip to main content

Table 2 The summarize of treatment doses and toxicities for the 14 patients received crizotinib treatment after acquired resistance to first generation EGFR-TKI

From: Crizotinib with or without an EGFR-TKI in treating EGFR-mutant NSCLC patients with acquired MET amplification after failure of EGFR-TKI therapy: a multicenter retrospective study

Patient no.

Age/gender

EGFR mutataion

Treatment after acquired resistance

Grade 3–4 toxicities

Reduce dose

1

55/male

21L858R

Icotinib 125 mg/tid + crizotinib 250 mg/bid

No

No

2

65/female

21L858R

Gefitinib 250 mg/qd + crizotinib 250 mg/bid

Aminotransferase rise

Gefitinib 250 mg/qd + crizotinib 200 mg/bid

3

53/male

21L858R

Icotinib 125 mg/tid + crizotinib 250 mg/bid

No

No

4

49/male

21L858R

Gefitinib 250 mg/qd + crizotinib 250 mg/bid

No

No

5

62/female

21L858R

Elotinib 150 mg/qd + crizotinib 250 mg/bid

Aminotransferase rise

Elotinib 150 mg/qd + crizotinib 200 mg/bid

6

60/female

19 exon deletion

Icotinib 125 mg/tid + crizotinib 250 mg/bid

No

No

7

37/male

19 exon deletion

Crizotinib 250 mg/bid

No

No

8

64/male

21L858R

Crizotinib 250 mg/bid

No

No

9

71/female

21L858R

Crizotinib 250 mg/bid

Nausea

Crizotinib 200 mg/bid

10

64/female

21L858R

Crizotinib 250 mg/bid

No

No

11

58/male

21L858R

Crizotinib 250 mg/bid

No

No

12

41/female

21L858R

Crizotinib 250 mg/bid

No

No

13

58/female

21L858R

Crizotinib 250 mg/bid

No

No

14

53/female

21L858R

Crizotinib 250 mg/bid

No

No